Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.

摘要: Cardiovascular disease is the leading cause of death among patients with stage 5 chronic kidney disease. Several mechanisms are thought to contribute vascular calcification and subsequent cardiovascular in who require hemodialysis. One these use calcium-containing phosphate binders treat hyperphosphatemia. Although most binding occurs gastrointestinal tract, some calcium inevitably absorbed has potential perpetuate calcium-phosphorus product development soft tissue calcification. Some such as sevelamer hydrochloride do not contain therefore may carry same risks. We examined effect morbidity mortality data compared when given for treatment A literature search using MEDLINE PubMed databases identified relevant articles from 1989-2009; nine studies between a binder hydrochloride. Three were also identified. Seven reported statistically significant increase taking measured by coronary artery scores aortic scores. In two trials, lower rates observed receiving binders. No difference rate was third trial. Based on current literature, it appears that promote progression greater extent than does addition, evidence suggests reduce all-cause undergoing hemodialysis, particularly those aged 65 years or older. Thus, although be more appropriate choice hemodialysis whom concern, clinical trials needed further guide practitioners selection